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Introduction: NSCLC is the leading cause of cancer mor-
tality. Recent retrospective clinical analyses suggest that
blocking the receptor activator of NF-kB (RANK) signaling
pathway inhibits the growth of NSCLC and might represent
a new treatment strategy.
Methods: Receptor activator of NF-kB gene (RANK) and
receptor activator of NF-kB ligand gene (RANKL) expression
in human lung adenocarcinoma was interrogated from
publicly available gene expression data sets. Several
genetically engineered mouse models were used to evaluate
treatment efﬁcacy of RANK-Fc to block RANKL, with
primary tumor growth measured longitudinally using
microcomputed tomography. A combination of RANKL
blockade with cisplatin was tested to mirror an ongoing
clinical trial.
Results: In human lung adenocarcinoma data sets, RANKL
expression was associated with decreased survival and
KRAS mutation, with the highest levels in tumors with co-
occurring KRAS and liver kinase B1 gene (LKB1) mutations.
In KrasLSL-G12D/WT, KrasLSL-G12D/WT; Lkb1Flox/Flox and
KrasLSL-G12D/WT; p53Flox/Flox mouse models of lung adeno-
carcinoma, we monitored an impaired progression of
tumors upon RANKL blockade. Despite elevated expression
of RANKL and RANK in immune cells, treatment
response was not associated with major changes in the
tumor immune microenvironment. Combined RANK-Fc
with cisplatin revealed increased efﬁcacy compared with
that of single agents in p53- but not in Lkb1-deﬁcient
tumors.
Conclusions: RANKL blocking agents impair the growth of
primary lung tumors in several mouse models of lung
adenocarcinoma and suggest that patients with KRAS-
mutant lung tumors will beneﬁt from such treatments. 2017 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Lung adenocarcinoma; RANK ligand; Genetically
engineered mouse models; Preclinical trial
Introduction
With more than 1.5 million deaths yearly, lung cancer
has become the leading cause of cancer-related mortality
worldwide, with NSCLC representing 80% to 85% of
cases.1 Although new therapies are emerging to combat
lung adenocarcinoma, which is the main histological
subtype of NSCLC, their use is currently limited to a subset
of molecularly selected patients, and no speciﬁc targeted
therapy has demonstrated activity against tumors car-
rying the most frequently mutated proto-oncogene,
KRAS.2 One interesting approach for cancer treatment isJournal of Thoracic Oncology Vol. 13 No. 3: 387-398
388 Faget et al Journal of Thoracic Oncology Vol. 13 No. 3to identify actionablemembrane-boundor secreted ligand-
receptor systems that act in the tumor environment to
promote disease progression,which can be very selectively
blocked through the use of small compounds or antibodies.
One such example is the tumornecrosis factor (TNF) family
member, receptor activator of NF-kB (RANK) ligand
(RANKL) that signals through its receptor RANK, which
was ﬁrst discovered for communication between T cells
and dendritic cells.3 Through its receptor RANK, RANKL
activates osteoclasts for bone resorption, promotes
lymphocyte maturation and function, and enables mam-
mary gland and secondary lymphnodeorganogenesis.4–6 A
link between RANKL signaling and cancer has been
established in recent years: ﬁrst, and perhaps owing to its
bone remodeling capabilities, the RANKL-RANK pathway
facilitates bone metastasis formation7,8; second, it pro-
motes seeding of breast tumor cells into the lungs in a
T-regulatory–cell-dependent manner9; third, it partici-
pates in development of progestin-dependent mammary
tumors.10,11 The importance of this signaling pathway in
primary breast cancer is well documented, with
RANKL mRNA being stabilized in response to progester-
one, leading to increased RANKL protein expression that
promotes tumor cell proliferation12 and epithelial-234 215 196 164 129 100 61
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Figure 1. Receptor activator of NF-kB ligand gene (RANKL) expre
human lung adenocarcinoma. (A) Kaplan–Meier curves for overall
of pairwise differences between groups with high or low RANKL
(TCGA) lung adenocarcinoma (right) data sets. Differences betwe
(B) RANKL expression level (log2) in the TCGA lung (left) and Pan
into two groups based on KRASmutation status (TCGA lung: muta
in Adjuvant Colon Cancer: MUT, n ¼ 283; WT, n ¼ 425). Statisti
RANKL expression level (log2) inmutant for KRAS and enriched for
kinaseB1gene (LKB1)mutations (KL), andmutant forKRASandenr
as deﬁned in Skoulidis et al.18 p Values are indicated. Statistical amesenchymal transition to foster tumor cell migration.13
In contrast, much less is known about its contribution in
primary tumors from other carcinomas such as lung
cancer. Recently, in a large international clinical trial of
patients with advanced solid tumors (excluding breast and
prostate cancer) or multiple myeloma, denosumab, a fully
humanmonoclonal antibody that binds RANKL and blocks
RANKL-RANK interaction, demonstrated activity in
preventing bone metastasis–related adverse events, such
as fracture or the need for radiotherapy. Although this trial
failed to reveal any difference in overall survival (OS),14 a
retrospective subgroup analysis from this trial reported
increasedOS speciﬁcally inpatientswithNSCLC.15,16 In our
study, we sought to investigate the involvement of RANKL
in primary tumors from NSCLC by using genetically
engineered mouse models.
Material and Methods
Animal Models
K-rasLSL-G12D/WT (K) and p53FL/FL mice in a C57BL6/J
background were purchased from The Jackson Labora-
tory (Bar Harbor, ME) and bred together to obtain
K-rasLSL-G12D/WT; p53FL/FL (KP) mice. Lkb1FL/FL mice in a
mixed background (FVB; 129S6) were obtained from R.nts
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Figure 2. Receptor activator of NF-kB (RANK) ligand blockade inhibits the growth of lung tumors in KrasLSL-G12D/WT and
KrasLSL-G12D/WT; Lkb1FL/FL mice. (A) Dot plots represent tumor growth, as measured by microcomputed tomography (mCT),
between initiation and end of treatment, in control Fc or RANK-Fc treated K-rasLSL-G12D/WT (K) (n ¼ 17 versus 18) and
KrasLSL-G12D/WT; Lkb1FL/FL (KL) (n ¼ 7 versus 7) mouse models. Treatment started at 23 and 18 weeks after tumor
initiation, respectively, and treatment duration is indicated. (B) Dot plot shows the percentage of Ki67-positive cells
among E-caderin–positive, CD45-negative viable tumor cells from K (left) or KL (right) tumors after treatment with control
Fc (K: n ¼ 8; KL: n ¼ 8) or RANK-Fc (K: n ¼ 10; KL: n ¼ 8). (C) Dot plots represent the percentage of phospho-Erk
(pErk)-positive area per lesion in K or KL mice treated with control-Fc (K: n ¼ 131; KL: n ¼ 16) or RANK-Fc (K: n ¼ 95;
KL: n ¼ 19). (D) Dot plots show number of cleaved caspase-3–positive cells per 106 pixels on lung tumor sections scanned
at 400. K (left) or KL (right) mice were treated with control-Fc (K: n ¼ 123; KL: n ¼ 15) or RANK-Fc (K: n ¼ 103; KL: n ¼ 18).
(E) Tumor growth monitoring by mCT over a 3-week period. KL mice were treated with control Fc or RANK-Fc. Eight and
seven tumors were monitored for Fc or RANK-Fc treatment, respectively. Curves represent volume evolution of each tumor,
as fold of the ﬁrst measurement. mCT imaging was done at weeks 0, 2, and 3 of treatment. Means with SE of the mean
are shown in the box. mCT images show lungs and the detectable tumors of two representative mice at weeks 0 and 3
of treatment. (A–E) Statistical analyses were performed by using the Mann-Whitney test; asterisks show p values: *p < 0.05,
**p < 0.01, ***p < 0.001. ns, not signiﬁcant.
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Figure 3. Receptor activator of NF-kB (RANK) ligand blockade elicits long-term antitumor response in KrasLSL-G12D/WT; p53FL/FL
mice. (A) Dot plots represent tumor growth, as measured by microcomputed tomography (mCT), between initiation and end
of treatment, in control Fc or RANK-Fc treated KrasLSL-G12D/WT; p53FL/FL (KP) mice (n ¼ 9 versus 15). Treatment started at 13
weeks after tumor initiation and lasted 1 week. (B) Dot plot represents the percentage of Ki67-positive cells among the
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March 2018 RANKL Signaling Sustains Lung Tumor Growth 391DePinho (The University of Texas M. D. Anderson Cancer
Center, Houston, Texas) through the National Cancer
Institute mouse repository, backcrossed seven times to
C57BL6/J, and bred with K-rasLSL-G12D/WT mice to obtain
K-rasLSL-G12D/WT; Lkb1FL/FL (KL) mice.
Mouse Treatment Modalities
Recombinant RANK (mouse):Fc (human) fusion and
human Fc immunoglobulin G1 control proteins were pur-
chased from AdipoGen Life Sciences (Liestal, Switzerland).
Micewere treated with 10mg/kg of RANK-Fc or Fc control
by subcutaneous injection twiceweekly. Cisplatinwasused
at 3.5 mg/kg in sterile phosphate-buffered saline by
intraperitoneal injection.
Study Approval
All mouse experiments were performed with
permission of the Veterinary Authority of the Canton de
Vaud, Switzerland (license number VD2391).
Results and Discussion
RANKL Expression Correlates with Poor OS and
KRAS Mutation in Lung Adenocarcinoma
To test the hypothesis that RANKL signaling regulates
the development of primary lung tumors, we interrogated
two independent publicly available gene expression data
sets of human lung adenocarcinoma, and one of colorectal
cancer (CRC). It revealed that high expression of RANKL
(also known as TNF superfamily member 11 gene
[TNFSF11]) was associated with a reduced OS compared
with that of tumor samples with low expression in lung
adenocarcinoma but not in CRC.RANK (also known as TNF
receptor superfamily member 11A [TNFRSF11A])
expression was also associated with reduced OS, but only
in one of the two lung data sets, whereas itwas linkedwith
better OS for patients with CRC (Fig. 1A and
Supplementary Fig. 1A–D), suggesting a peculiar rela-
tionship between RANK/RANKL signaling and lung can-
cer progression that is not shared by CRC. Speciﬁc data
analysis from The Cancer Genome Atlas (TCGA [https://
tcga-data.nci.nih.gov/tcga/]) also showed that RANKL
expression was signiﬁcantly stronger in KRAS-mutant
than in KRAS wild-type (WT) tumors in lung adenocarci-
noma but not in CRC (Fig. 1B). KRASmutation itself in lung
adenocarcinoma is not prognostic of poor OS as reportedE-cadherin (E-cad)-positive, CD45-negative cells from KP tumors
(n¼ 16). (C) Dot plot represents the percentage of phospho-Erk–
control-Fc (n ¼ 27) or RANK-Fc (n ¼ 116). (D) Tumor growth mo
during the last 6 weeks with control Fc or RANK-Fc. A total of 17
volume evolution of each tumor as fold of the ﬁrst measurement.
treatment started atweek 0.Meanswith SE of themean are show
the Mann-Whitney test; asterisks show p values: *p < 0.05, **p <earlier17 (Supplementary Fig. 1E). Recently, gene expres-
sion analysis from TCGA enabled to deﬁne biologically
distinct KRAS-mutant lung tumors in function of co-
occurring mutations in tumor suppressors.18 Speciﬁcally,
this analysis highlighted three different subgroups, called
KC (mutant for KRAS and enriched for CDKN2Amutations),
KP (mutant for KRAS and enriched for TP53 mutations),
and KL (mutant for KRAS and enriched for liver kinase B1
gene [LKB1] mutations). Analogies were drawn between
cluster-speciﬁc biological signatures and tumors from
different mouse models of oncogenic Kras-dependent lung
tumorigenesis. For example, gene set enrichment analysis
of the KL cluster retrieved gene signatures obtained from
murine lung tumors expressing mutant Kras(G12D) and
deﬁcient for Lkb1.18 Intrigued by these analogies, we
decided to compare RANKL expression between each
cluster. This analysis showed that RANKL levels are
signiﬁcantly higher in the KL cluster than in the KP cluster
(p¼ 9.6e-07 [Fig. 1C]). From each of the KRAS-mutant and
KRASWTgroup, aswell as from the KC, KL, and KP clusters
fromKRAS-mutant tumors,we interrogated the genesmost
positively correlated with RANKL (Supplementary
Table 1). This analysis revealed hallmark pathways of
cell cycle, mammalian target of rapamycin signaling,
epithelial-mesenchymal transition (EMT), hypoxia, and
glycolysis in theKRAS-mutant samples. In contrast,RANKL-
correlated genes in KRAS WT tumor samples revealed
pathways representing EMT, inﬂammatory and angiogenic
responses, and interestingly, KRAS signaling. KRAS-mutant
subgroup analysis highlighted further differences between
the clusters, with enrichments for pathways of cell cycle
and EMT in KC; cell cycle and mammalian target of rapa-
mycin signaling in KL; and inﬂammatory and immune re-
sponses, KRAS signaling, and EMT in KP (see
Supplementary Table 1). Thus, RANKL expression, which
is stronger in KRAS-mutant samples than in KRAS WT
samples, is associated with poor OS in human lung
adenocarcinoma. Within KRAS-mutant tumors, expression
of RANKL is the strongest in a subgroup of tumors
harboring LKB1 mutations.
Pharmacological Blockade of Rankl Inhibits
Tumor Growth in Mouse Models of Lung
Adenocarcinoma
The human data prompted us to investigate the pos-
sibility that RANKL signaling contributes to primaryafter 1 week of treatment with control Fc (n ¼ 8) or RANK-Fc
positive area on lesions from KPmice treated over 1 week with
nitoring by mCTover an 8-week period. KP mice were treated
tumors were monitored for each treatment. Curves represent
mCT imaging started 2 weeks before treatment initiation, and
n in the box. (A–D) Statistical analyseswere performed by using
0.01, ***p < 0.001.
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Figure 4. Tumor and immune cells differentially express receptor activator of NF-kB (Rank) ligand (Rankl) and Rank. (A)
Immunohistochemistry pictures of frozen lung sections from tumor-bearing K-rasLSL-G12D/WT (K), KrasLSL-G12D/WT; p53FL/FL (KP),
or KrasLSL-G12D/WT; Lkb1FL/FL (KL) mice showing Rank (top) or Rankl (bottom) expression (brown) in tumors. Original magni-
ﬁcation: large pictures, 100; small pictures, 500. (B) Dot plots show Rankl (left) and Rank (right) gene relative expression
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we decided to block Rankl-Rank interaction with a re-
combinant protein composed of the extracellular portion
of mouse RANK fused to human Fc (RANK-Fc), ﬁrst in
two genetically engineered mouse models of NSCLC,
K-rasLSL-G12D/WT (designated as K hereafter) and
K-rasLSL-G12D/WT; Lkb1FL/FL (KL). In these models, tumor
initiation is triggered in adult mice upon intratracheal
delivery of viruses carrying the Cre recombinase, result-
ing in oncogenic Kras(G12D) activation (K), or Kras(G12D)
activation concomitantly with deletion of tumor sup-
pressor Lkb1 (KL). Loss of Lkb1 enables tumor progres-
sion toward aggressive adenocarcinoma, with
transdifferentiation to squamous cell carcinoma in some
cases.19–21 For preclinical relevance, mice were treated
with RANK-Fc or control Fc only when tumors were well
established and visible by microcomputed tomography
(mCT). Short-term (2 weeks for K and 1 week for KLmice)
RANK-Fc treatment led to a signiﬁcantly diminished
tumor growth rate, with tumor shrinkage (i.e., relative
growth<1) detected in multiple tumors, as monitored by
mCT (Fig. 2A). This response was accompanied by a
reduced proliferation of tumor cells (Ki67 staining) and
reduced phospho-Erk, a marker of advanced grade in
Kras-mutant lung tumors,22,23 speciﬁcally in KL tumors.
No change in apoptosis in K or KL tumorswas observed, as
assessed by cleaved caspase-3 staining (Fig. 2B–D). Next,
to determine whether there is rapid tumor progression
after initial sensitivity to Rankl inhibition, we treated the
most aggressive model twice weekly with RANK-Fc or
control Fc for a total duration of 3 weeks and monitored
tumor growth rates longitudinally by mCT. Tumor growth
remained compromised, indicating a durable response of
primary lung adenocarcinoma to Rankl blockade (Fig. 2E).
Hence, Kras-mutant lung tumors, whether expressing or
not expressing Lkb1, are sensitive to Rankl blockade.Rankl Blockade Elicits Long-Term Antitumor
Responses in K-rasLSL-G12D/WT; p53FL/FL Mice
To evaluate the antitumor effects of Rankl
blockade in yet another model, we treated tumor-bearing
K-rasLSL-G12D/WT; p53FL/FL (KP) mice24 with RANK-Fc.from real-time polymerase chain reaction on K (n ¼ 18), KP (
noﬂuorescence pictures showing Rank (left) or Rankl (right) in
(blue) staining in KP tumors. (D) Representative immunoﬂuore
together with CD45 (green) and Hoechst (blue) staining in KP t
Rank relative mRNA expression from nonimmune (CD45-negative
and Rank relative mRNA expression of sorted CD45-negative (n ¼
and Rank relative mRNA abundance in sorted CD3-positive T c
CD45-positive myeloid cells from KP tumors. Histograms repr
denote SE of the mean; n ¼ 4, 4, and 7 experiments, respectiv
and Rank relative mRNA expression in CD45-negative and CD45-p
mice. Treatment started at 23 weeks after tumor initiation, an
were performed by using the Mann-Whitney test. *p <0.05, **pSimilarly to the effect observed in K and KL mice, KP
tumors were inherently sensitive to short-term Rankl
blockade, although no change in tumor cell proliferation
contrasting with that in KL tumors could be measured
(Fig. 3A and B). Surprisingly, phospho-Erk was enhanced,
suggesting a paradoxical Erk-dependent pathway acti-
vation in response to Rankl blocking therapy in KP tu-
mors (Fig. 3C). A 6-week treatment follow-up indicated a
long-term response to Rankl blockade in KP mice
(Fig. 3D). Together, the results from Figures 2 and 3
demonstrate an inherent sensitivity and durable
response to Rankl blockade in primary lung tumors in
the mouse.
Rankl-Rank Expression Is Elevated in Tumor-
Associated Immune Cells, but Blockade Does Not
Lead to Major Changes in the Tumor Immune
Microenvironment
Next, we decided to better characterize the effect
of Rankl blockade. Staining of tumor sections by immu-
nohistochemistry showed Rank and Rankl expression in
each of the K, KP, and KL tumors (Fig. 4A). Monitoring by
real-time polymerase chain reaction did not reveal any
difference in Rankl expression between the tumor geno-
types, although there was stronger Rank expression in KP
than in K or KL tumors, thus contrasting with the human
TCGA data (Fig. 4B). Immunoﬂuorescence staining
enabled us to detect each of Rank and Rankl plasma
membrane protein expression heterogeneously within
the tumor mass, with Rank frequently colocalizing with
E-cadherin and Rankl with CD45-positive (immune) cells
(Fig. 4C–D). To understandwhich cell types express Rankl
and Rank, we collected lung tumors or healthy lung from
KP mice and used anti-CD45 magnetic beads to separate
nonimmune (CD45-negative) from immune (CD45-
positive) cells. This revealed a stronger expression of
Rankl in CD45-negative cells isolated from tumors (which
consist mostly but not exclusively of tumor epithelial
cells) than in CD45-negative cells from healthy lung,
whereas Rank expression was not different (Fig. 4E). In
tumors, expression of Rankl and Rank was more elevated
in immune than in nonimmune cells, with the strongestn ¼ 15), and KL (n ¼ 19) tumors. (C) Representative immu-
green together with E-cadherin (E-cad) (red) and Hoechst
scence pictures showing Rank (left) or Rankl (right) in red
umors. (C and D) Original magniﬁcation, 200. (E) Rankl and
) cells of normal lung (n ¼ 5) or KP tumors (n ¼ 11). (F) Rankl
11) or CD45-positive (n ¼ 6) cells from KP tumors. (G) Rankl
ells, B220-positive B cells, and CD3-negative B220-negative
esent the average of multiple experiments and error bars
ely for T-cell, B-cell, and myeloid cell populations. (H) Rankl
ositive cells of tumors from control Fc or RANK-Fc treated KP
d duration was 2 weeks. (B, E, F, and H) Statistical analyses
<0.01, ***p < 0.001. Rel., relative; Tum, tumor.
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Figure 5. Receptor activator of NF-kB (Rank) ligand (Rankl) blockade increases chemotherapy efﬁcacy in KrasLSL-G12D/WT;
p53FL/FL (KP) tumors. (A) Dot plot shows tumor growth, determined by microcomputed tomography imaging, in KP mice
treated or not during 1 week with Fc control (Fc-CTR) (n ¼ 19), RANK-Fc (n = 22), or cisplatin (Cis) (n = 19). (B) Dot plot shows
tumor growth, determined by microcomputed tomography imaging, in KP mice treated by a combination of control Fc
(n ¼ 19) or RANK-Fc (n ¼ 22) plus Cis. Mice received Fc or RANK-Fc injections during a 2-week period plus one injection of Cis
during the last week. (C) Relative mRNA abundance of the indicated genes in CD45-negative or CD45-positive sorted cells of
tumors obtained from KP mice treated in (B). Error bars show SE of the mean. Statistical analyses comparing CD45-positive
versus CD45-negative fractions were not performed. (D) Dot plot shows cleaved caspase-3–positive cell number per 106 pixels,
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myeloid cells for Rank (Fig. 4F–G). Because of this strong
expression in immune cells within lung tumors, we next
wanted to know whether treatment causes remodeling of
the tumor immune microenvironment. RANK-Fc led to a
signiﬁcant increase in Rankl expression in nonimmune
cells and a reduction in immune cells, whereas there was
no perturbation in Rank expression (Fig. 4H). After 2
weeks of treatment, no change was observed in the pro-
portion of B cells, whereas that of T lymphocytes dimin-
ished, which was not speciﬁc for any of the CD4-positive,
T-regulatory, or CD8-positive subsets (Supplementary
Fig. 2A–C). Rankl blockade did not result in any signiﬁ-
cant change in the expression of tumor necrosis factor
gene (Tnf), interleukin 10 gene (Il10), or interferon
gamma gene (Ifng) mRNAs in CD45-positive or CD45-
negative cells and did not alter cytoplasmic expression
of interferon gamma or tumor necrosis factor proteins in
CD4-positive or CD8-positive T cells (Supplementary
Fig. 2D and E). RANK was originally characterized in
dendritic cells and suggested to participate in dendritic
cell–dependent T-cell expansion, a hypothesis that was
not supported by analysis of Rank-deﬁcient mice.3,4 Our
results demonstrate that despite elevated Rank and Rankl
expression in immune cells within the tumor microenvi-
ronment, Rankl blockade only marginally remodels the
immune compartment, which does not support a major
role for immune cells in the antitumor response.
Rankl Blockade Increases the Efﬁcacy of
Cisplatin Chemotherapy
To test the effect of combination treatment compared
with monotherapy, we decided to treat tumor-bearing
KP mice with RANK-Fc for 1 week followed by 1 week
of standard chemotherapy cisplatin with maintenance of
RANK-Fc and used mCT to compare tumor growth rates
with those of tumors from mice treated with cisplatin
alone. Short-term cisplatin caused a diminished tumor
growth rate, as reported earlier,25 which was not
signiﬁcantly different from RANK-Fc therapy (Fig. 5A).
Combined RANK-Fc and cisplatin led to a more profound
effect on tumor growth (Fig. 5B). When compared with
cisplatin alone, combined therapy led to a signiﬁcant
decrease in the expression of the antiapoptotic genes
Bcl-2-like protein 1 gene (Bcl2l1) and X-linked inhibitor
of apoptosis gene (Xiap) in the tumor cell compartment,in KP mice treated as in (B). Control-Fc plus phosphate-buffered
PBS (n ¼ 12), and RANK-Fc plus Cis (n ¼ 22). (E) Model of RAN
response to Rankl blockade is additive with Cis, resulting in d
deﬁcient tumors, Rankl blockade inhibits Erk activity and tumo
by using Mann-Whitney test. Asterisks show statistical p values:
mut, mutated; Bcl2l1, Bcl-2-like protein 1 gene; Xiap, X-link
apoptosis regulator gene.as well as to Xiap in immune cells and increased
apoptosis revealed by cleaved caspase-3 (Fig. 5C and D).
In contrast, there was no additive effect of the combi-
nation treatment compared with that of chemotherapy
alone in KL tumors, maybe because RANK-Fc diminishes
tumor cell proliferation and hence does not favor success
of an antiproliferative drug (Supplementary Fig. 3).
Hence, our results highlight the efﬁcacy of Rankl
blockade in preclinical mouse models of lung adenocar-
cinoma. They suggest different mechanisms of action in
different tumor molecular subtypes and that combina-
tion treatments will be more efﬁcacious than chemo-
therapy alone in some but not all patients (Fig. 5E).
Bcl2l1andXiapare knownNF-kB target genes. Signaling
by NF-kB directly in the tumor epithelial cells plays an
important role in the development of lung tumors inmouse
models of NSCLC, notably in tumors initiated upon onco-
genic Kras activation.26–32 However, how the NF-kB
pathway becomes activated in NSCLC is currently unclear.
Because NF-kB most often responds to cell stimulation by
extracellular ligands such as cytokines of the interleukin-1
or TNF families, one plausible scenario is that the tumor
microenvironment triggers NF-kB activation in tumor cells
by paracrine communication. As it is a potent activator of
NF-kB, RANKL could participate in the elaboration of an
NF-kB response in lung tumor cells.15 Indeed, RANKL
stimulates migration of the A549 human lung tumor cell
line through the upregulation of the NF-kB target gene
intercellular adhesionmolecule 1 gene (ICAM1).33 In future
preclinical and clinical investigations, it will therefore be
important to test whether RANKL participates in lung tu-
mor development partly through NF-kB activation, and
whether NF-kB targets could be used as biomarkers of
denosumab treatment efﬁcacy in patients’ tumors.
In our study, we have used mouse models where
tumor initiation depends on oncogenic Kras activation,
because (1) KRAS is the most commonly mutated proto-
oncogene in human NSCLC, (2) these models faithfully
recapitulate many aspects of the development of the
human disease, and (3) these models are refractory to
many treatments and are thus relevant to assess new
therapeutic opportunities (here Rankl blockade). Our
preclinical results, combined with our bioinformatics
analyses, depict a strong connection between mutant
KRAS and RANKL signaling in lung adenocarcinoma,
which probably does not take place in CRC. Hence, oursaline (PBS) (n ¼ 10), control-Fc plus Cis (n ¼ 19), RANK-Fc þ
KL signaling in lung tumor cells. In p53-deﬁcient tumors, the
ecreased tumor cell survival. In liver kinase B1 gene (Lkb1)-
r cell proliferation. (A–D) Statistical analyses were performed
*p < 0.05, **p < 0.01. ns, not signiﬁcant; pERK, phospho-ERK;
ed inhibitor of apoptosis gene; Cﬂar, CASP8 and FADD like
396 Faget et al Journal of Thoracic Oncology Vol. 13 No. 3observations are generating the hypothesis that RANKL
blockade will be efﬁcient in KRAS-mutant lung tumors.
An important future step will be to verify this hypothesis
directly in tumor samples from patients.
Case Report of a Patient with Stage IV NSCLC
Treated with Denosumab Monotherapy
A female patient, who was a former smoker with a 30-
pack-year smoking history, presented with a middle lobe
lung adenocarcinoma, EGFR WT, without anaplastic lym-
phoma receptor tyrosine kinase gene (ALK) rearrange-
ment, cT4 cN0 cM1b (lower right lobe and bone
metastases in the thoracolumbar spine especially L3,
pelvis, femoral collar) stage IV. The adenocarcinoma was
diagnosed on March 15, 2013 (by a transbronchial biopsy
lower right lobe). The patient was hesitant regarding
chemotherapy. Although she was presenting several
painful bone metastases, an initial treatment of denosu-
mab monotherapy was introduced as the ﬁrst step in her
oncology management, in parallel with supportive care
including lumbar spine palliative radiotherapy in March.
She decided to start chemotherapy on May 21, which was
2 months after the diagnosis. A new computed tomogra-
phy scan was performed before she started undergoing
chemotherapy, 4weeks after a unique cycle of denosumab
only, showing a primary lung tumor partial response
(Fig. 6A and B). Thereafter, she received systemicFigure 6. Clinical efﬁcacy of denosumab monotherapy in a pa
the thorax of a chemotherapy-naive patient with stage IV NS
lobe secondary lesion (B) before (left) and after (right) a sin
response 4 weeks after a single infusion.chemotherapy (10 cycles [four platinum-pemetrexed and
6 pemetrexed], with partial response and thereafter with
stable disease). She died 7 months after diagnosis.
This clinical case illustrates the potential efﬁcacy, at
least in select cases, of RANKL blockade therapy, even in
advanced disease as monotherapy. Furthermore, the
very large unplanned retrospective analysis of denosu-
mab versus zoledronic acid in bone metastatic lung
cancer16 and our gene expression data set analyses of
human lung adenocarcinoma both support the hypoth-
esis of an improved OS. The activity of denosumab as an
antineoplastic drug for the treatment of advanced NSCLC
in combination with frontline platinum-based chemo-
therapy is currently being evaluated in the large
randomized phase 3 European Organization for Research
and Treatment of Cancer/European Thoracic Oncology
Platform trial SPLENDOUR, with a primary end point of
OS and a parallel retrospective analysis of RANK
signaling pathway activation, including RANK and
RANKL expression at baseline for all patients.
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